Celldex Therapeutics, Inc. Earnings Dividend

Celldex Therapeutics, Inc.’s revenue fell -96.99% since last year same period to $0.02Mn in the Q2 2026. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 46.67% jump in its revenue since last 3-months.

Celldex Therapeutics, Inc.’s net profit fell -29.86% since last year same period to $-73.5Mn in the Q2 2026. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 6.59% jump in its net profits since last 3-months.

Celldex Therapeutics, Inc.’s net profit margin fell -4209.12% since last year same period to -334104.55% in the Q2 2026. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 36.31% jump in its net profit margins since last 3-months.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.04 - a 7.96% jump from last quarter’s estimates.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.04.

Celldex Therapeutics, Inc.’s earning per share (EPS) fell -10.59% since last year same period to -0.94 in the Q2 2026. This indicates that the Celldex Therapeutics, Inc. has generated -10.59% annual rate of fall in its earning per share (EPS) in the last 4 quarters.